The abstract submission system is now closed!
Abstract submission deadlines
Date and time
26 September 2023, 21:00hrs CEST
Late breaking abstracts (LBA)
Final submission deadline* 2 November 2023, 21:00hrs CET
*A preliminary abstract indicating the data expected to be available by the LBA deadline must be submitted online by 26 September 2023 as an “intent to submit a late-breaking abstract”.
Outcome notifications are expected to be made available to first authors and submitters by end-October 2023.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-November 2023.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-October in the section “Information for Presenters”.
Abstract submission categories
- Biomarker development
- Cell therapy immune engineering
- Clinical practice
- Therapeutic development
- Tumour biology and tumour microenvironment
Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 26 September 2023 will be considered for late-breaking status.
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2023.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The ESMO Immuno-Oncology Congress 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Immuno-Oncology Congress 2023 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).
Publication schedule for accepted abstracts
Details regarding the publication of accepted abstracts are available here.
ESMO Merit Travel Grants
A limited number of Merit Travel Grants to the ESMO Immuno-Oncology Congress 2023 are available, upon application, to first authors (= presenters) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Immuno-Oncology Congress 2023 Scientific Committee on a competitive basis from among the accepted abstracts.